-

At Physicians' Education Resource®, LLC ( PER®), our comprehensive activities are designed utilizing adult education principles to ensure that the learning objectives and outcomes are identified, measured, and achieved.

PER® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PER® is approved by the California Board of Registered Nursing, Provider #16669.

PER® maintains complete responsibility and control over all content, quality, and scientific integrity of its educational activities and plans, develops, implements, and evaluates them in accordance with the Accreditation Council for Continuing Medical Education (ACCME)’s Essential Areas and Elements, Policies and Standards for Commercial SupportSM, as well as guidelines set forth by the American Medical Association (AMA), California Board of Registered Nursing (CBRN), US Food and Drug Administration (FDA), US Department of Health and Human Services Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA) and the Advanced Medical Technology Association (AdvaMed).

Disclosure Policy

It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities.

In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to start of each activity.

Participants are notified prior to the activity of any relationship or absence of a relationship between faculty and commercial interests. Information disclosed includes the name of the faculty, the nature of the affiliation or financial interest, and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support to the participants.

• Medical_Professionals
• Medical_students
• Nurses

In 2017, groundbreaking research continues to revolutionize treatment approaches and modalities across oncology disciplines. Within the diverse specialties of surgical, medical, and radiation oncology, a conference for clinicians who manage some of the most difficult-to-treat forms of gastrointestinal (GI) cancers is of particular value. The School of Gastrointestinal Oncology™ (SOGO™), a program focused exclusively on these tumors, takes the latest advances in research, and provides an educational venue that facilitates the practical application of new evidence to improve outcomes in your patients. This intensive 1-day, multi-track, curriculum-based, conference demonstrates how the latest data can be seamlessly incorporated into contemporary practice settings where patients with GI cancers receive care.

SOGO™ prides itself on its multidisciplinary focus, featuring multiple break out tracks dedicated to medical, surgical, and radiation oncology, as well as a nursing track. Attendees are brought together repeatedly throughout the day, allowing for a shared learning experience in sessions that aim to address your most difficult clinical scenarios. Now in its third year, our expert faculty will integrate the latest data on prognostic and predictive markers and how these data impact clinical decision-making on evolving treatment strategies into a case-based format. Our goal is your goal, to optimize outcomes for each one of your patients with GI cancers. See you in New York!

What you’ll learn at SOGO™ 2018!

How disease pathology and actionable biomarkers inform clinical decision-making

Advances in surgery including new frontiers in minimally invasive techniques

The expanding role that molecularly targeted and immunotherapeutic approaches are playing in GI cancers treatment

Optimized sequencing strategies to personalize care for your patients

Contemporary use of multidisciplinary approaches to optimize patient outcomes in advanced forms of GI cancers

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Target Audience

This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is gastrointestinal (GI) cancers, and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, gastroenterologists, or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

INTERCONTINENTAL NEW YORK TIMES SQUARE

300 West 44th Street (and 8th Avenue)

New York, NY

(877) 331-5888

Be sure to mention the School of Gastrointestinal Oncology™ when making reservations to receive the discounted rate.

Location 

The INTERCONTENTIAL NEW YORK TIMES SQUARE is located near La Guardia Airport (LGA), John F. Kennedy International Airport (JFK), and Newark Liberty International Airport (EWR).

Submission Info

Contact No.: (609) 378-3701

Email: info@gotoper.com

Contact No.: (609) 378-3701

Email: info@gotoper.com